United States: FDA Issues Draft Guidances For Prior Approval Supplements And Amendments / Easily Correctable Deficiencies Under GDUFA

The Generic Drug User Fee Amendments of 2012 (GDUFA) were signed into law on July 9, 2012, in an effort "to speed access to safe and effective generic drugs to the public and reduce costs to industry." In July 2014, the U.S. Food and Drug Administration (FDA) issued two draft Guidances for Industry: one relating to Prior Approval Supplements Under GDUFA and one relating to Amendments and Easily Correctable Deficiencies Under GDUFA.

Prior Approval Supplements Under GDUFA

Prior approval supplements (PASs) and amendments to PASs for abbreviated new drug applications (ANDAs) are submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 355(j)). The FDA issued the following performance metric goals for PASs submissions:

  • If an inspection is not needed, the goal is six months from the date of submission.
  • If an inspection is needed, the goal is 10 months from the date of submission.

The FDA hopes to review and act on 60 percent of PAS submissions in fiscal year 2015, 75 percent of PAS submissions in fiscal year 2016 and 90 percent of PAS submissions in fiscal year 2017. However, these performance metric goals apply only to ANDA holders that submit a PAS on or after October 1, 2014. They do not apply to an amendment to a PAS if the PAS was submitted prior to that date. These performance metric goals also do not apply to new drug applications or biologics license applications or to supplements thereto. If an amendment is made to a PAS, the GDUFA goal date may be revised by the FDA.

The submission date is defined as the date that the PAS arrives in the appropriate electronic portal of the FDA. The FDA will then count this submission date as the first day of the review period and will calculate the goal date in months. If FDA refuses to receive a PAS, the GDUFA review clock will stop. The applicant can then submit a corrected or new supplement, but a new GDUFA fee will be required and a new review clock will start, resulting in a new goal date for that PAS.

The following events can result in the FDA's refusal to receive a PAS:

  • failure to pay the application fee within 20 calendar days of submission;
  • reference to a drug master file (DMF) that is not on the public available for reference list;
  • reference to a facility on the facility arrears list;
  • the applicant is the owner or is affiliated with the owner of a facility on the facility arrears list; or
  • the applicant is on or affiliated with an entity on the backlog arrears list.

If a PAS is substantially complete except for failure to pay the PAS user fee, the PAS will be deemed received when the fee is paid. Similarly, if a PAS is substantially complete but references a facility on the arrears list, the PAS will be deemed received once the facility is removed from that list.

Determining whether an inspection is required for a PAS is within the discretion of the FDA and depends, in part, on the nature of the supplement. If the PAS involves a facility not approved in the original ANDA or if it involves a fundamental change to the manufacturing process or technology, an inspection may be required. FDA, however, will rely on previous inspections of a finished product site if it occurred within two years of the current Good Manufacturing Practice (cGMP) evaluation for a pending application, three years for an active pharmaceutical ingredient (API) site or control testing laboratory and four years for a packaging-only site. Some exceptions may apply to this general practice, depending on the nature of the drug being processed or the complexity of the processing operations.

The FDA considers multiple supplements submitted to multiple ANDAs by a single applicant for the same chemistry, manufacturing and controls change to each ANDA to be a "grouped supplement." However, each supplement in this group is considered an individual submission and requires its own GDUFA fee for each ANDA in the group. That being said, the submissions will generally have the same GDUFA goal date.

If a supplement is filed as a Changes Being Effected (CBE) but the FDA finds that such submission should have been submitted as a PAS, the FDA will notify the applicant and then administratively close and withdraw the CBE. The applicant may then resubmit the supplement as a PAS, along with the required GDUFA fee. The GDUFA review clock will run from the date of submission of the PAS.

Amendments and Easily Correctible Deficiencies Under GDUFA

The FDA has issued the following performance metric goals for amendments submitted electronically to original ANDAs and PASs filed on or after October 1, 2014.

For original ANDAs or PASs submitted before October 1, 2014, these performance goals are inapplicable to subsequently filed amendments thereto. Where these goals apply, such amendments may add additional time to the original ANDA review, but in no case will they shorten the original goal date. The time periods above are calculated from the date of submission of the amendment.

"A solicited amendment is a submission made by an applicant in response to a complete response letter (CR) issued by FDA." These amendments are classified as either Tier 1 or Tier 3 and either as a major amendment, a minor amendment or an easily correctable deficiency (ECD). A major amendment "contain[s] a substantial amount of new data or new information not previously submitted to reviewed by FDA, requiring ... a substantial expenditure of FDA resources." The first solicited major amendment is classified as Tier 1; any subsequent major amendment is classified as Tier 3. Appendix A of the Draft Guidance provides a nonexhaustive list of deficiencies that generally require major amendments. A minor amendment, on the other hand, "requires ... fewer FDA resources than are necessary to review a major amendment but more than are necessary to review the information submitted in response to an ECD." For instance, a minor amendment may address missing information but not require any new studies to be performed. The first through fifth solicited minor amendments are classified as Tier 1; any subsequent minor amendment is classified as Tier 3. Appendix B of the Draft Guidance provides a nonexhaustive list of deficiencies that generally require minor amendments. Any Tier 3 amendment, whether major or minor, will cause the ANDA to lose its goal date. Finally, ECDs "require[] ... a modest expenditure of FDA resources." They can be responded to quickly because the applicant should already have the necessary information. ECDs generally relate to requests for clarification, requests for postapproval commitments or final resolution of technical issues. ECDs do not extend the goal date. Appendix C of the Draft Guidance provides a nonexhaustive list of deficiencies that are generally ECDs.

"An unsolicited (gratuitous) amendment is submitted on the applicant's own initiative and not in response to FDA's CR letter." These amendments are classified as either delaying or nondelaying. All delaying amendments are Tier 1 and all non-delaying amendments are Tier 2. A delaying amendment "address[es] actions by a third party that would cause delay or impede application review or approval timing and that were not a factor at the time of submission." Delaying amendments do not add to the count of major or minor amendments. A nondelaying amendment "contain[s] information that is not requested by FDA and is not the result of changes to the RLD or USP monograph, changes to the RLD labeling, a REMS and REMS modification, or generic approval requirements reflected in citizen petition responses issued by FDA."

By contrast, an administrative amendment is "routine in nature and do[es] not require scientific review." These types of amendments include "[r]equests for final approval with no scientific changes to the ANDA, patent amendments, and general correspondence submitted by applicants." These amendments do not affect goal dates.

An applicant may request reconsideration of an amendment classification. If an applicant seeks reconsideration of a CR amendment, a written request for a post-CR-letter meeting must be sent to the regulatory project manager within 10 business days of issuance of the CR letter. The applicant will then be required to submit meeting materials that adequately explain the nature of the request. The division will issue a decision within 10 business days. If the request is granted after an amendment has been submitted and a review is pending, the change in classification will not alter the goal date but will adjust the amendment count. If the amendment has not yet been submitted, it will be assigned the revised classification and corresponding goal date. If an applicant seeks reconsideration of a change in classification after submission of a CR amendment, the request should be made in writing within 10 business days from issuance of the goal letter and contain adequate information to explain the nature of the dispute. The division will make a decision on this request within 10 business days, and if rendered, such a change in classification will not alter the goal date but will adjust the amendment count. If an applicant disagrees with the decision on reconsideration, it may file a formal appeal of the decision.

The Draft Guidance provides a series of useful examples for how these amendment goals are applied. It also provides an amendment flow chart that graphically depicts the different types of amendments and their effect on the goal date.

If you have any questions about this Alert, please contact Frederick (Rick) R. Ball, Carolyn A. Alenci, any member of the Pharmaceutical, Medical Device, Pharmacy & Food industry group or the attorney in the firm with whom you are regularly in contact.

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions